Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide

@inproceedings{Rodrigueza2014DevelopmentAA,
  title={Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide},
  author={Wendi V. Rodrigueza and Michael J. Woolliscroft and Abdul-Shukkur Ebrahim and Robert Forgey and Patrick J. McGovren and Gerold Dr. Endert and Andreas Peter Wagner and Danielle D. Holewa and Amro Aboukameel and Richard D. Gill and Charles L. Bisgaier and Richard A. Messmann and Christopher E. Whitehead and Elzbieta Izbicka and Robert Streeper and Michael C. Wick and Gabriela Stiegler and C. A. Stein and David J. Monsma and Craig Paul Webb and Mina Patel Sooch and Steffen Dr. Panzner and Ramzi M. Mohammad and Neal Clifford Goodwin and Ayad Al-Katib},
  booktitle={Cancer Chemotherapy and Pharmacology},
  year={2014}
}
PNT100 is a 24-base, chemically unmodified DNA oligonucleotide sequence that is complementary to a region upstream of the BCL-2 gene. Exposure of tumor cells to PNT100 results in suppression of proliferation and cell death by a process called DNA interference. PNT2258 is PNT100 that is encapsulated in protective amphoteric liposomes developed to efficiently encapsulate the PNT100 oligonucleotide, provide enhanced serum stability, optimized pharmacokinetic properties and antitumor activity of… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

Unintended target effect of anti-BCL-2 DNAi

  • Cancer management and research
  • 2017
VIEW 2 EXCERPTS
CITES METHODS & BACKGROUND

Future therapeutic options for patients with Waldenström macroglobulinemia.

  • Best practice & research. Clinical haematology
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND

Hematologic malignancies: newer strategies to counter the BCL-2 protein

  • Journal of Cancer Research and Clinical Oncology
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 61 REFERENCES

Jawadi n, alKatib a (1993) a unique eBV- negative low-grade lymphoma

Mohammad rM, Mohamed an, Smith Mr
  • Cancer Chemother Pharmacol
  • 2014
VIEW 1 EXCERPT

Targeting the Bcl-2 family for cancer therapy.

  • Expert opinion on therapeutic targets
  • 2013
VIEW 1 EXCERPT

a, rauchhaus U et al (2013) treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes

arranz a, C reinsch, Papadakis Ka, Dieckmann
  • J Control release
  • 2013

Maurano Mt (2012) the accessible chromatin landscape of the human genome

thurman re, rynes e, Humbert r, H Vierstra
  • 2012

Targeting the B-cell lymphoma/leukemia 2 family in cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012